Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
|Videos|November 24, 2016
Future Applications of Immunotherapy
Author(s)Contagion Editorial Staff
Marcos Pires, PhD, assistant professor at Lehigh University, discusses future applications of immunotherapy.
Advertisement
Marcos Pires, PhD, assistant professor at Lehigh University, discusses future applications of immunotherapy.
Interview Transcript (slightly modified for readability)
“I think, if anything, the great success immunotherapies against cancer is teaching us, is that there’s no reason to believe that [immunotherapy] can’t be evaluated for a number of diseases, where you have cells or pathogens you’d like to remove from the system. It will probably be the case that there is a version of an agent or a therapy that can go after bacteria. I imagine the same can be true for viruses, [and] perhaps for fungal infections as well.
It’s unclear if there’s a real limit [to what illnesses immunotherapies can fight], because after all, if you think about what it’s doing, it’s just strengthening a protective feature that we have already.”
Advertisement
Related to this article
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Advertisement
Advertisement
Trending on Contagion Live
1
Russian Lab Worker Dies in Suspected Pneumonic Plague Case
2
Long-Acting Cabotegravir/Rilpivirine Superior to Daily Oral ART for HIV
3
FAQ: Pneumonic Plague
4
From Pathogen to Infectious Disease Diagnosis: Multispecies Immunoblot Nearly Doubles Early Lyme Disease Detection
5